EP1295944A3 - GDP-Dissoziation stimulierendes Protein, gehirnspezifisches Nucleosomfügungsprotein, Skelettmuskel-spezifisches Ubiquitin-Conjugationsenzym, Zellproliferationsprotein, Phosphatidylinositolkinase, Nel verwandte Proteine - Google Patents

GDP-Dissoziation stimulierendes Protein, gehirnspezifisches Nucleosomfügungsprotein, Skelettmuskel-spezifisches Ubiquitin-Conjugationsenzym, Zellproliferationsprotein, Phosphatidylinositolkinase, Nel verwandte Proteine Download PDF

Info

Publication number
EP1295944A3
EP1295944A3 EP02026841A EP02026841A EP1295944A3 EP 1295944 A3 EP1295944 A3 EP 1295944A3 EP 02026841 A EP02026841 A EP 02026841A EP 02026841 A EP02026841 A EP 02026841A EP 1295944 A3 EP1295944 A3 EP 1295944A3
Authority
EP
European Patent Office
Prior art keywords
protein
specific
phosphatidylinositolkinase
nel
brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP02026841A
Other languages
English (en)
French (fr)
Other versions
EP1295944A2 (de
EP1295944B1 (de
Inventor
Tsutomu Fujiwara
Takeshi Watanabe
Masato Horie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Priority to EP10185775A priority Critical patent/EP2361982A1/de
Priority to EP10182760A priority patent/EP2272960A1/de
Priority to EP07014998A priority patent/EP1860189A1/de
Priority to EP04004141A priority patent/EP1439230A3/de
Publication of EP1295944A2 publication Critical patent/EP1295944A2/de
Publication of EP1295944A3 publication Critical patent/EP1295944A3/de
Application granted granted Critical
Publication of EP1295944B1 publication Critical patent/EP1295944B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
EP02026841A 1996-03-19 1997-03-19 GDP-Dissoziation stimulierendes Protein, gehirnspezifisches Nucleosomfügungsprotein, Skelettmuskel-spezifisches Ubiquitin-Conjugationsenzym, Zellproliferationsprotein, Phosphatidylinositolkinase, Nel verwandte Proteine Expired - Lifetime EP1295944B1 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP10185775A EP2361982A1 (de) 1996-03-19 1997-03-19 Menschliches Gen, kodierend für Ubiquitin konjugierendes Enzym
EP10182760A EP2272960A1 (de) 1996-03-19 1997-03-19 Menschliche Protein NELL2 Gen
EP07014998A EP1860189A1 (de) 1996-03-19 1997-03-19 Menschliches Gen
EP04004141A EP1439230A3 (de) 1996-03-19 1997-03-19 Menschliche transmembranprotein TMP-2 gen

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP6341096 1996-03-19
JP6341096 1996-03-19
JP6916397 1997-03-05
JP06916397A JP3646191B2 (ja) 1996-03-19 1997-03-05 ヒト遺伝子
EP97104842A EP0796913A3 (de) 1996-03-19 1997-03-19 GDP-Dissoziation stimulierendes Protein, gehirnspezifisches Nucleosomfügungsprotein, Skelettmuskel-spezifisches Ubiquitin-Conjugationsenzym, Zellproliferationsprotein, Phosphatidylinositolkinase, Nel verwandte Proteine

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP97104842A Division EP0796913A3 (de) 1996-03-19 1997-03-19 GDP-Dissoziation stimulierendes Protein, gehirnspezifisches Nucleosomfügungsprotein, Skelettmuskel-spezifisches Ubiquitin-Conjugationsenzym, Zellproliferationsprotein, Phosphatidylinositolkinase, Nel verwandte Proteine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP04004141A Division EP1439230A3 (de) 1996-03-19 1997-03-19 Menschliche transmembranprotein TMP-2 gen

Publications (3)

Publication Number Publication Date
EP1295944A2 EP1295944A2 (de) 2003-03-26
EP1295944A3 true EP1295944A3 (de) 2004-04-21
EP1295944B1 EP1295944B1 (de) 2007-05-16

Family

ID=26404531

Family Applications (6)

Application Number Title Priority Date Filing Date
EP04004141A Withdrawn EP1439230A3 (de) 1996-03-19 1997-03-19 Menschliche transmembranprotein TMP-2 gen
EP02026841A Expired - Lifetime EP1295944B1 (de) 1996-03-19 1997-03-19 GDP-Dissoziation stimulierendes Protein, gehirnspezifisches Nucleosomfügungsprotein, Skelettmuskel-spezifisches Ubiquitin-Conjugationsenzym, Zellproliferationsprotein, Phosphatidylinositolkinase, Nel verwandte Proteine
EP07014998A Withdrawn EP1860189A1 (de) 1996-03-19 1997-03-19 Menschliches Gen
EP10182760A Withdrawn EP2272960A1 (de) 1996-03-19 1997-03-19 Menschliche Protein NELL2 Gen
EP97104842A Ceased EP0796913A3 (de) 1996-03-19 1997-03-19 GDP-Dissoziation stimulierendes Protein, gehirnspezifisches Nucleosomfügungsprotein, Skelettmuskel-spezifisches Ubiquitin-Conjugationsenzym, Zellproliferationsprotein, Phosphatidylinositolkinase, Nel verwandte Proteine
EP10185775A Withdrawn EP2361982A1 (de) 1996-03-19 1997-03-19 Menschliches Gen, kodierend für Ubiquitin konjugierendes Enzym

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP04004141A Withdrawn EP1439230A3 (de) 1996-03-19 1997-03-19 Menschliche transmembranprotein TMP-2 gen

Family Applications After (4)

Application Number Title Priority Date Filing Date
EP07014998A Withdrawn EP1860189A1 (de) 1996-03-19 1997-03-19 Menschliches Gen
EP10182760A Withdrawn EP2272960A1 (de) 1996-03-19 1997-03-19 Menschliche Protein NELL2 Gen
EP97104842A Ceased EP0796913A3 (de) 1996-03-19 1997-03-19 GDP-Dissoziation stimulierendes Protein, gehirnspezifisches Nucleosomfügungsprotein, Skelettmuskel-spezifisches Ubiquitin-Conjugationsenzym, Zellproliferationsprotein, Phosphatidylinositolkinase, Nel verwandte Proteine
EP10185775A Withdrawn EP2361982A1 (de) 1996-03-19 1997-03-19 Menschliches Gen, kodierend für Ubiquitin konjugierendes Enzym

Country Status (8)

Country Link
US (7) US5831058A (de)
EP (6) EP1439230A3 (de)
JP (1) JP3646191B2 (de)
AT (1) ATE362536T1 (de)
CA (2) CA2200371C (de)
DE (1) DE69737740T2 (de)
DK (1) DK1295944T3 (de)
ES (1) ES2284770T3 (de)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410506B1 (en) * 1995-05-19 2002-06-25 Human Genome Sciences, Inc. Transforming growth factor α HII
US20030170864A1 (en) * 2000-05-30 2003-09-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO1998027205A2 (en) * 1996-12-18 1998-06-25 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
US5976837A (en) * 1997-03-14 1999-11-02 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
US5863779A (en) * 1997-08-21 1999-01-26 Incyte Pharmaceuticals, Inc. UBC7-like ubiquitin-conjugating enzyme
AU3045099A (en) * 1998-03-27 1999-10-18 University Of Leeds, The Ubiquitin conjugating enzyme
US6171790B1 (en) 1998-05-01 2001-01-09 Incyte Pharmaceuticals, Inc. Human protease associated proteins
JP2000109433A (ja) * 1998-08-05 2000-04-18 Otsuka Pharmaceut Co Ltd 神経変性疾患治療剤
EP1141285A2 (de) * 1998-12-16 2001-10-10 Genentech, Inc. Ausgeschiedene und transmembran-polypeptide und dafür kodierende nukleinsäure
WO2000065052A1 (en) * 1999-04-22 2000-11-02 Habener Joel F Bridge-1, a transcription factor
WO2004072100A2 (en) * 2003-02-07 2004-08-26 The Regents Of The University Of California Nell peptide expression systems and bone formation activity of nell peptide
US7884066B2 (en) * 1999-10-05 2011-02-08 The Regents Of The University Of California NELL-1 enhanced bone mineralization
WO2001069261A2 (en) * 2000-03-15 2001-09-20 Oxford Glycosciences (Uk) Ltd. Proteins, genes and their use for diagnosis and treatment of vascular dementia
US6689877B2 (en) * 2000-11-06 2004-02-10 The Board Of Regents Of The University Of Nebraska Methods and compositions for the treatment of human immunodeficiency virus infection
US20030039968A1 (en) * 2001-07-10 2003-02-27 Applera Corporation Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
US20040049024A1 (en) * 2001-12-07 2004-03-11 Geoff Clark Compositions and methods related to the minn1 tumor suppressor gene and protein
ATE545428T1 (de) 2002-12-16 2012-03-15 Develogen Ag Pik4cb involviert in der regulierung des energiestoffwechsels
US7691607B2 (en) * 2004-02-09 2010-04-06 The Regents Of The University Of California Expression system of NELL peptide
KR101200133B1 (ko) 2004-06-01 2012-11-13 제넨테크, 인크. 항체 약물 접합체 및 방법
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
CA2580141C (en) 2004-09-23 2013-12-10 Genentech, Inc. Cysteine engineered antibodies and conjugates
JP4993645B2 (ja) 2004-12-01 2012-08-08 ジェネンテック， インコーポレイテッド 抗体薬剤結合体および方法
NZ584514A (en) * 2007-10-19 2012-07-27 Genentech Inc Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
ES2595364T3 (es) 2008-10-07 2016-12-29 The Regents Of The University Of California Producción de proteínas NELL recombinantes
IN2012DN03025A (de) 2009-09-09 2015-07-31 Ct Se Llc
BR112012026213B1 (pt) 2010-04-15 2021-12-28 Medimmune Limited Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa
CA2799540A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
JP5889912B2 (ja) 2010-11-17 2016-03-22 ジェネンテック， インコーポレイテッド アラニニルメイタンシノール抗体コンジュゲート
CA2833212C (en) 2011-05-12 2020-06-09 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides
KR101877598B1 (ko) 2011-10-14 2018-07-11 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨주게이트
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
ES2703151T3 (es) 2012-10-12 2019-03-07 Adc Therapeutics Sa Conjugados de anticuerpos de pirrolobenzodiazepinas
NZ707486A (en) 2012-10-12 2018-09-28 Adc Therapeutics Sa Pyrrolobenzodiazepine - anti-psma antibody conjugates
ES2660029T3 (es) 2012-10-12 2018-03-20 Medimmune Limited Conjugados de anticuerpo-pirrolobenzodiazepinas
HUE035694T2 (en) 2012-10-12 2018-05-28 Adc Therapeutics Sa Pirrolobenzodiazepine anti-CD22 antibody conjugates
SI2906296T1 (en) 2012-10-12 2018-06-29 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
EP2906250B1 (de) 2012-10-12 2018-05-30 ADC Therapeutics SA Pyrrolobenzodiazepin-anti-psma-antikörperkonjugate
PT2839860T (pt) 2012-10-12 2019-07-29 Medimmune Ltd Pirrolobenzodiazepinas e conjugados das mesmas
EA031585B1 (ru) 2012-12-21 2019-01-31 Медимьюн Лимитед Пирролобензодиазепины и их конъюгаты
CN105246894A (zh) 2012-12-21 2016-01-13 斯皮罗根有限公司 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
JP6444902B2 (ja) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びその結合体
NZ710745A (en) 2013-03-13 2019-03-29 Genentech Inc Pyrrolobenzodiazepines and conjugates thereof
CN105142674B (zh) 2013-03-13 2018-11-13 麦迪穆有限责任公司 吡咯并苯并二氮杂卓和其结合物
AU2014307080B2 (en) 2013-08-12 2018-06-07 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1H-benzo(E)indole dimer antibody-drug conjugate compounds, and methods of use and treatment
EP3054985B1 (de) 2013-10-11 2018-12-26 Medimmune Limited Pyrrolobenzodiazepin-antikörper-konjugate
EP3054983B1 (de) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepin-antikörper-konjugate
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2015052535A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
CA2929565A1 (en) 2013-12-16 2015-06-25 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
JP6895254B2 (ja) 2013-12-16 2021-06-30 ジェネンテック， インコーポレイテッド ペプチド模倣化合物及びその抗体−薬物コンジュゲート
CA2928952A1 (en) 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
CN104189884A (zh) * 2014-08-19 2014-12-10 承德医学院 Urantide的应用
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US10077318B2 (en) 2014-09-12 2018-09-18 Genentech, Inc. Cysteine engineered antibodies and conjugates
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
EP3191134B1 (de) 2014-09-12 2019-11-20 Genentech, Inc. Anthracyclindisulfidzwischenprodukte, antikörper-wirkstoff-konjugate und verfahren
MA40575A (fr) 2014-09-17 2016-03-24 Genentech Inc Pyrrolobenzodiazépines et conjugués à base de disulfure d'anticorps associés
AU2015352545B2 (en) 2014-11-25 2020-10-15 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
WO2016090050A1 (en) 2014-12-03 2016-06-09 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP6943872B2 (ja) 2016-03-25 2021-10-06 ジェネンテック， インコーポレイテッド 多重全抗体及び抗体複合体化薬物定量化アッセイ
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP2019522633A (ja) 2016-05-20 2019-08-15 ジェネンテック， インコーポレイテッド Ｐｒｏｔａｃ抗体コンジュゲート及び使用方法
US20170370906A1 (en) 2016-05-27 2017-12-28 Genentech, Inc. Bioanalytical analysis of site-specific antibody drug conjugates
EP3464280B1 (de) 2016-06-06 2021-10-06 F. Hoffmann-La Roche AG Silvestrol-antikörper-arzneimittelkonjugate und verfahren zur verwendung
EP3496763A1 (de) 2016-08-11 2019-06-19 Genentech, Inc. Pyrrolobenzodiazepin-prodrugs und antikörperkonjugate davon
EP3522933B1 (de) 2016-10-05 2021-12-15 F. Hoffmann-La Roche AG Verfahren zur herstellung von antikörperarzneimittelkonjugaten
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
RS61795B1 (sr) 2017-02-08 2021-06-30 Adc Therapeutics Sa Konjugati pirolobenzodiazepin antitela
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
WO2018192944A1 (en) 2017-04-18 2018-10-25 Medimmune Limited Pyrrolobenzodiazepine conjugates
EP3612234B1 (de) 2017-04-20 2024-03-13 ADC Therapeutics SA Kombinationstherapie mit anti-axl-antikörper-arzneimittel-konjugat
MX2019015042A (es) 2017-06-14 2020-08-06 Adc Therapeutics Sa Regimen de dosificacion.
AU2018316532B2 (en) 2017-08-18 2022-11-24 Medimmune Limited Pyrrolobenzodiazepine conjugates
IL273387B2 (en) 2017-09-20 2023-10-01 Ph Pharma Co Ltd Thylanstatin analogs
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
JP2022505450A (ja) 2018-10-24 2022-01-14 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト コンジュゲート化された化学的分解誘導物質および使用方法
WO2020123275A1 (en) 2018-12-10 2020-06-18 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05268957A (ja) 1992-03-27 1993-10-19 Bio Material Kenkyusho:Kk ラット多機能プロテアーゼ構成因子およびそのｄｎａ
JP3125235B2 (ja) 1992-04-22 2001-01-15 株式会社バイオマテリアル研究所 ヒト２６ｓプロテアソーム
JPH05317059A (ja) 1992-05-22 1993-12-03 Bio Material Kenkyusho:Kk ラットプロテアソームのコンポーネントおよび そのｄｎａ
US5470577A (en) * 1993-07-07 1995-11-28 Trustees Of Boston University Stimulation of tanning by DNA fragments or single-stranded DNA
AU713364B2 (en) * 1995-05-19 1999-12-02 Human Genome Sciences, Inc. Transforming growth factor alpha HII
US5863779A (en) * 1997-08-21 1999-01-26 Incyte Pharmaceuticals, Inc. UBC7-like ubiquitin-conjugating enzyme
WO2004072100A2 (en) * 2003-02-07 2004-08-26 The Regents Of The University Of California Nell peptide expression systems and bone formation activity of nell peptide

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
HILLIER ET AL.: "yx19d04.r1 cDNA clone", EMBL DATABASE , ACCESSION NUMBER HS045260, 30 December 1995 (1995-12-30), XP002145500 *
HILLIER L. ET AL.: "yd85f10.rl cDNA clone - similar to mouse guanine nucleotide dissociation stimulator", EMBL DATABASE , ACCESSION NUMBER HS60650, 1 April 1995 (1995-04-01), XP002145499 *
ISOMURA M ET AL: "Isolation and mapping of RAB2L, a human cDNA that encodes a protein homologous to RaIGDS.", CYTOGENETICS AND CELL GENETICS, vol. 74, no. 4, 1996, pages 263 - 265, XP000938401, ISSN: 0301-0171 *
PETERSON SCOTT N ET AL: "Identification of a novel RalGDS-related protein as a candidate effector for Ras and Rap1.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 47, 1996, pages 29903 - 29908, XP000919221, ISSN: 0021-9258 *
SPAARGAREN MARCEL ET AL: "Identification of the guanine nucleotide dissociation stimulator for Ra1 as a putative effector molecule of R-ras, H-ras, K-ras, and rap.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 91, no. 26, 1994, 1994, pages 12609 - 12613, XP002145498, ISSN: 0027-8424 *
WONG K ET AL: "Cloning and characterization of a human phosphatidylinositol 4-kinase.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. UNITED STATES 18 NOV 1994, vol. 269, no. 46, 18 November 1994 (1994-11-18), pages 28878 - 28884, XP002066663, ISSN: 0021-9258 *
ZHOU K ET AL: "A phosphatidylinositol (PI) kinase gene family in Dictyostelium discoideum: biological roles of putative mammalian p110 and yeast Vps34p PI 3-kinase homologs during growth and development.", MOLECULAR AND CELLULAR BIOLOGY. UNITED STATES OCT 1995, vol. 15, no. 10, October 1995 (1995-10-01), pages 5645 - 5656, XP002270498, ISSN: 0270-7306 *

Also Published As

Publication number Publication date
US20100048878A1 (en) 2010-02-25
JPH09308492A (ja) 1997-12-02
DE69737740T2 (de) 2008-01-31
CA2641565C (en) 2012-11-13
EP1295944A2 (de) 2003-03-26
JP3646191B2 (ja) 2005-05-11
EP0796913A3 (de) 2001-01-31
EP0796913A2 (de) 1997-09-24
US7592438B2 (en) 2009-09-22
DK1295944T3 (da) 2007-09-17
US8048995B2 (en) 2011-11-01
EP1439230A2 (de) 2004-07-21
US7674889B2 (en) 2010-03-09
DE69737740D1 (de) 2007-06-28
ES2284770T3 (es) 2007-11-16
ATE362536T1 (de) 2007-06-15
US20060134634A1 (en) 2006-06-22
US20100160611A1 (en) 2010-06-24
EP1860189A1 (de) 2007-11-28
US7858754B2 (en) 2010-12-28
US5831058A (en) 1998-11-03
EP1439230A3 (de) 2004-09-22
EP1295944B1 (de) 2007-05-16
CA2200371C (en) 2007-07-10
US8106171B2 (en) 2012-01-31
US20080032337A1 (en) 2008-02-07
CA2641565A1 (en) 1997-09-19
US20070111285A1 (en) 2007-05-17
US20110105718A1 (en) 2011-05-05
EP2361982A1 (de) 2011-08-31
CA2200371A1 (en) 1997-09-19
EP2272960A1 (de) 2011-01-12

Similar Documents

Publication Publication Date Title
EP1295944A3 (de) GDP-Dissoziation stimulierendes Protein, gehirnspezifisches Nucleosomfügungsprotein, Skelettmuskel-spezifisches Ubiquitin-Conjugationsenzym, Zellproliferationsprotein, Phosphatidylinositolkinase, Nel verwandte Proteine
HUP0004611A2 (hu) APRIL, egy új növekedési hatású fehérje
BG109433A (en) RET (RetL) Lead for Stimulating Nerve and Rat Growth
ZA988124B (en) Mage-3 peptides presented by HLA class II molecules
WO1998031800A3 (en) Human proteins
EP1005540A4 (de) Ikk-beta proteines, nukleinsäuren und verfahren
BG100771A (en) Hematopoeic protein and ways and methods for its preparation
ATE319818T1 (de) Polypeptide mit aminopeptidaseaktivität und für diese kodierende nukleinsäuren
AU1724795A (en) Human tissue inhibitor of metalloproteinase-4
AU7635096A (en) Materials and methods relating to the identification and sequencing of the brca2 cancer susceptibility gene and uses thereof
WO1999053061A3 (en) Tumor associated nucleic acids and uses therefor
WO1998014596A3 (en) Disease associated protein tyrosine phosphatases
MX9602977A (es) Proteinas que reparan la mala union de adn humano.
AU9291198A (en) Apoptosis-related compounds and their use
DE69736389T8 (de) Proteine mit zellulase-aktivitäten und prozess für ihre herstellung
WO1999010504A3 (en) Caspase-14, an apoptotic protease, nucleic acids encoding and methods of use
WO2000008157A3 (en) Human anion transporter genes atnov
EP0261403A3 (de) Polypeptide des Rhinovirusstammes HRV89 sowie die hierfür codierenden DNA-Moleküle
AU8811298A (en) Novel peptides and polypeptides useful for regenerating the nervous system
AU5327198A (en) Nucleotide sequence coding for a flavin-containing monooxygenase, corresponding protein and their applications in the fields of diagnosis and therapy
MY132368A (en) Malathion carboxylesterase
EP1074621A4 (de) Menschliches tsc403 gen und menschliches ing1l gen
WO1997001634A3 (en) Polypeptide for repairing genetic information, nucleotidic sequence which codes for it and process for the preparation thereof (guanine thymine binding protein - gtbp)
WO1998056810A3 (de) Humanes protein lus-i, seine herstellung und verwendung
EP1428833A3 (de) 207 menschliche sekretierte Proteine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021129

AC Divisional application: reference to earlier application

Ref document number: 0796913

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AKX Designation fees paid

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AC Divisional application: reference to earlier application

Ref document number: 0796913

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070516

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: OTSUKA PHARMACEUTICAL CO., LTD.

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: CH

Ref legal event code: NV

Representative=s name: SERVOPATENT GMBH

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69737740

Country of ref document: DE

Date of ref document: 20070628

Kind code of ref document: P

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

ET Fr: translation filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2284770

Country of ref document: ES

Kind code of ref document: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070516

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20071016

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: OTSUKA PHARMACEUTICAL CO., LTD.

Free format text: OTSUKA PHARMACEUTICAL CO., LTD.#9, KANDATSUKASACHO 2-CHOME#CHIYODA-KU TOKYO 101 (JP) -TRANSFER TO- OTSUKA PHARMACEUTICAL CO., LTD.#9, KANDATSUKASACHO 2-CHOME#CHIYODA-KU TOKYO 101 (JP)

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20080219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070817

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080319

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20080319

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20140311

Year of fee payment: 18

Ref country code: CH

Payment date: 20140312

Year of fee payment: 18

Ref country code: NL

Payment date: 20140208

Year of fee payment: 18

Ref country code: DK

Payment date: 20140311

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20140307

Year of fee payment: 18

Ref country code: AT

Payment date: 20140226

Year of fee payment: 18

Ref country code: ES

Payment date: 20140211

Year of fee payment: 18

Ref country code: FR

Payment date: 20140311

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20140319

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20140417

Year of fee payment: 18

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 69737740

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20150331

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 362536

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150319

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20150319

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150320

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20150401

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150319

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20151130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151001

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150331

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150319

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150331

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150319

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20160427

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150320

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150401